Inhibition of UBE2C Promotes Parkin-Mediated K63-Linked Ubiquitination of TOP2A to Induce Senescence and Increase Sensitivity of Doxorubicin in Breast Cancer.

ABSTRACT: Breast cancer is now the second most commonly diagnosed cancer and the most common female malignancy. Chemotherapy-based adjuvant therapy after surgery and neoadjuvant therapy before surgery are cornerstones of breast cancer treatment. Doxorubicin is one of the most commonly used anthracycline chemotherapy treatments for breast cancer; however, doxorubicin resistance is a major barrier to its clinical use. Therefore, there is an urgent need to discover new targets to overcome doxorubicin resistance in breast cancer. Ubiquitin-conjugating enzyme 2C (UBE2C) is an E2 ubiquitin-conjugating enzyme that catalyzes the assembly of K11-linked ubiquitin chains. In recent years, dysregulation of UBE2C has been implicated in a variety of cancers, including breast cancer; however, the underlying mechan

SUBMITTER: Yang Y 

PROVIDER: S-EPMC12407369 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature